# Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63

> **NCT00369031** · PHASE1 · TERMINATED · sponsor: **St George's, University of London** · enrollment: 31 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** Human Immunodeficiency Virus glycoprotein 140 (vaccine)
- **BIOLOGICAL:** HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant
- **BIOLOGICAL:** Labile Toxin mutant LTK63 adjuvant

## Key facts

- **NCT ID:** NCT00369031
- **Lead sponsor:** St George's, University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2007-11
- **Final completion:** 2008-03
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Safety issues
- **Last updated:** 2008-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369031, "Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00369031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*